

AERIE PHARMACEUTICALS INC  
Form 8-K/A  
April 13, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 12, 2017 (April 12, 2017)**

**Aerie Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-36152**  
**(Commission**  
**File Number)**  
**2030 Main Street, Suite 1500**

**20-3109565**  
**(I.R.S. Employer**  
**Identification Number)**

**Irvine, California 92614**

Edgar Filing: AERIE PHARMACEUTICALS INC - Form 8-K/A

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (949) 526-8700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### EXPLANATORY NOTE

Aerie Pharmaceuticals, Inc. (the Company) is furnishing this Amendment No. 1 to its Current Report on Form 8-K (Amendment No. 1) furnished with the SEC on April 12, 2017 (the Original Form 8-K), to refurnish the slides describing the six-month topline results of Rocket 4 because Slide 9 in Exhibit 99.2 included in the Original Form 8-K included only the Company's logo. The slides presented by management and available on the Company's website (aeriepharma.com) remain unchanged.

#### **Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit shall be deemed to be furnished, and not filed:

99.1 Rhopressa™ (netarsudil ophthalmic solution) 0.02% Rocket 4 Phase 3 6-Month Topline Results.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AERIE PHARMACEUTICALS, INC.**

Date: April 12, 2017

By: /s/ Richard J. Rubino  
Richard J. Rubino  
Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	Rhopressa™ (netarsudil ophthalmic solution) 0.02% Rocket 4 Phase 3 6-Month Topline Results.